- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Impact of Weight Loss on NAFLD: Is there a Dose-Response Relationship?
Weight loss is known to improve markers of fatty liver disease but authors of a recent meta-analysis took their investigation deeper. Scan through the research to the findings.
In the absence of pharmacotherapies for nonalcoholic fatty liver disease (NAFLD), weight loss is the primary intervention recommended and is known to be successful, with greater weight reduction associated with greater improvements in a range of disease markers.
Against this background, authors of a meta-analysis published recently in Metabolism Clinical and Experimental looked further to identify the relationship between magnitude of weight loss and improvements in NAFLD. We break down the study for easy-reading in the slides that follow.
Slide image ©Kateryna_Kon/stock.adobe.com
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
